Cagrilintide and tirzepatide work on entirely different receptors — amylin vs GLP-1/GIP — which means this cagrilintide vs tirzepatide comparison isn't just academic: it determines which options are available to you today, subject to medical approval by a licensed provider at TelosRX.
Both names dominate weight-loss research in 2026. Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is FDA-approved with a mature evidence base. Cagrilintide is investigational — best known as one half of the CagriSema combination — and not available outside clinical trials. That distinction has real consequences for what you can access today.
Two Completely Different Mechanisms of Action
Tirzepatide is a dual agonist. It binds both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GLP-1 slows gastric emptying, suppresses appetite through hypothalamic pathways, and reduces glucagon secretion. GIP complements this through effects on fat-cell function and energy expenditure via brown adipose tissue thermogenesis. Together, they produce one of the strongest appetite-suppression and glycemic-control profiles seen in a single approved molecule.
Cagrilintide is a long-acting synthetic analog of amylin — a 37-amino-acid peptide co-secreted alongside insulin from pancreatic beta cells after meals. It acts on the area postrema and nucleus tractus solitarius in the brainstem: satiety centers anatomically and functionally separate from the hypothalamic pathways where GLP-1 receptors concentrate. These receptor systems don't overlap. That non-overlap is precisely why researchers study cagrilintide as a combination partner for GLP-1 therapies, not a replacement for them.
Put simply: GLP-1/GIP agonists suppress appetite through the gut-brain axis and the hypothalamus. Amylin analogs suppress appetite through the brainstem's dedicated satiety circuit. They operate in parallel, not in competition.
Cagrilintide vs Tirzepatide: Head-to-Head Comparison
| Feature | Cagrilintide | Tirzepatide |
|---|---|---|
| Receptor target | Amylin receptor complex (CALCR/RAMP1-3) | GLP-1 receptor + GIP receptor (dual agonist) |
| Half-life | ~7 days (once-weekly) | ~5 days (once-weekly) |
| FDA approval status | Investigational — Phase 3 trials only | FDA-approved (Mounjaro 2022 / Zepbound 2023) |
| Peak monotherapy efficacy | Limited Phase 2 monotherapy data | Up to 22.5% body weight (SURMOUNT-1) |
| Best-evidenced use case | Combination with semaglutide (CagriSema) | Standalone weight management and T2D control |
| Primary side effects | Nausea, injection-site reactions | Nausea, vomiting, diarrhea, constipation |
| Compounded availability | Not available — investigational only | Available via compounding (not FDA-approved compound) |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
The Clinical Evidence: What Trials Actually Showed
Tirzepatide has the deeper evidence base. The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults with obesity and reported up to 22.5% mean body weight reduction at 15 mg over 72 weeks (Jastreboff et al., NEJM 2022). SURMOUNT-2 through -4 extended the evidence to people with type 2 diabetes and longer-term maintenance. The SURPASS program further established glycemic efficacy across five large trials.
Cagrilintide's most compelling data comes from combination studies. A Phase 2 trial published in The Lancet in 2021 evaluated escalating-dose CagriSema (cagrilintide + semaglutide 2.4 mg weekly) against each component alone over 32 weeks. CagriSema produced ~17.1% mean weight reduction — substantially more than either agent alone — suggesting additive or synergistic appetite-suppression effects from hitting two distinct receptor systems.
Then came the landmark REDEFINE 4 Phase 3 trial: a direct head-to-head comparison. Key outcomes:
- CagriSema: ~20.2% weight reduction (treatment-regimen estimand); ~23.0% (efficacy estimand)
- Tirzepatide: ~23.6% weight reduction (treatment-regimen estimand); ~25.5% (efficacy estimand)
Tirzepatide edged ahead in this comparison. But an amylin + GLP-1 combination reaching ~23% efficacy at Phase 3 scale confirms that non-incretin mechanisms can be clinically competitive — a meaningful finding for where the field goes next.
FDA Status: What Approval Actually Means for Access
FDA approval determines what's prescribable and through what pathway — not just a regulatory formality.
Tirzepatide received FDA approval as Mounjaro in May 2022 (type 2 diabetes) and as Zepbound in November 2023 (chronic weight management). Approval followed large Phase 3 trials demonstrating safety and efficacy, and it enables licensed providers to prescribe it commercially. Compounded tirzepatide — prepared by licensed compounding pharmacies under federal compounding regulations — is not itself FDA-approved as a compounded product, but may be evaluated and prescribed through telehealth platforms subject to medical approval by a licensed provider.
Cagrilintide has no FDA approval for any indication as of mid-2026. Access is limited to enrolled participants in ongoing clinical trials. There is no commercial or compounded cagrilintide pathway.
Why Non-Overlapping Receptor Pathways Matter
When two compounds act through entirely different receptor systems, they don't compete for binding sites. Independent pathways can produce additive appetite suppression — which is the logic behind CagriSema and behind research interest in triple-mechanism approaches (amylin + GLP-1 + GIP).
GLP-1 and GIP agonism involve the gut-brain axis: vagal afferents, the nucleus accumbens, and the hypothalamus. Amylin receptor signaling targets the caudal brainstem — the area postrema, which lacks a blood-brain barrier and directly detects circulating satiety signals. These are parallel circuits, not competing ones. An agent already saturating GLP-1 receptors can still produce additional suppression through amylin's brainstem pathway.
This principle explains why the CagriSema Phase 2 data showed more weight loss than either component alone, and why researchers are exploring whether cagrilintide can someday augment tirzepatide's already-impressive GLP-1/GIP dual mechanism.
Side Effect Profiles and Tolerability
Both compounds share a predominantly GI side effect profile — not coincidental, since both slow gastric emptying through different mechanisms with overlapping downstream GI effects.
Tirzepatide (SURMOUNT-1 data): Nausea in approximately 24–33% of participants at therapeutic doses, vomiting (~9–12%), diarrhea (~13–17%), constipation (~11%). Effects are dose-dependent and most prominent during escalation. Rare events include pancreatitis. Preclinical studies identified thyroid C-cell tumors in rodents; clinical significance in humans has not been established.
Cagrilintide (Phase 2 data): Nausea and injection-site reactions are most commonly reported. Long-term safety data is still accumulating through REDEFINE Phase 3 trials. The overall tolerability profile appears broadly comparable to GLP-1 receptor agonists in available data.
Provider-guided dose titration is the primary tolerability strategy for both agents. Slow escalation allows the GI tract to adapt. Without appropriate titration, early dropout rates increase substantially — a practical consideration for any protocol involving these compounds.
Pharmacokinetics: Half-Life, Dosing, and Escalation
Both are once-weekly subcutaneous injections. The ~7-day half-life of cagrilintide versus tirzepatide's ~5-day half-life means cagrilintide achieves somewhat steadier plasma levels across the dosing week. In practice, both support predictable once-weekly regimens.
Dose escalation schedules differ. Tirzepatide starts at 2.5 mg weekly, increasing in 2.5 mg increments every 4 weeks to a maximum of 15 mg (approximately 20 weeks to target). Cagrilintide in REDEFINE protocols starts at 0.25 mg and escalates to 2.4 mg weekly over approximately 16 weeks. Both protocols prioritize tolerability, not speed to target dose.
Muscle Preservation: A Shared Consideration
Significant weight loss from any pharmacological approach includes some lean mass reduction. GLP-1-class agents are no exception. Early SURMOUNT trial analyses suggested approximately 14% of total weight lost came from lean tissue. Preserving muscle mass during a GLP-1-supported weight-loss protocol requires adequate protein intake (studies suggest 1.2–1.6g/kg/day) and consistent resistance training. This principle applies regardless of whether the agent is tirzepatide, CagriSema, or any future combination. For a deeper look, see our guide to muscle preservation on GLP-1 therapy.
The Research Horizon
The REDEFINE program continues. REDEFINE 1 evaluates CagriSema for weight management without T2D. REDEFINE 2 focuses on T2D. REDEFINE 3 targets cardiovascular outcomes — data that will determine whether CagriSema's efficacy profile translates to the kind of cardiovascular risk reduction demonstrated in the SELECT trial for semaglutide.
Separately, mechanistic research is exploring amylin + GLP-1 + GIP triple combinations — whether cagrilintide can augment tirzepatide rather than semaglutide. The rationale is sound; human clinical trial data does not yet exist (ClinicalTrials.gov). For context on the broader GLP-1 pipeline, see our review of retatrutide and the triple-agonist pipeline.
Which to Consider: A Practical Framework
The right answer depends on what's available, your medical history, and what a licensed provider determines after a full evaluation. Here's where the evidence currently lands:
- Tirzepatide today: FDA-approved with extensive Phase 3 evidence. Accessible through licensed telehealth providers — including compounded formulations prepared under federal compounding regulations (not FDA-approved compounds) — subject to provider evaluation.
- CagriSema to watch: Compelling Phase 3 data, regulatory filings anticipated. Not accessible outside clinical trials in 2026.
- Cagrilintide + tirzepatide combination: Mechanistically interesting; no human clinical trial data; not available outside research settings.
If you're ready to explore GLP-1 options available through asynchronous telehealth today, start your evaluation at TelosRX — all subject to review by a licensed provider, with no guaranteed approval. You can also compare context on tirzepatide vs semaglutide to understand how these GLP-1 class options differ from each other.
Frequently Asked Questions
Is cagrilintide FDA approved?
No. Cagrilintide has not received FDA approval for any indication as of mid-2026. It is currently in Phase 3 clinical trials through the REDEFINE program — in combination with semaglutide. No commercial or compounded formulation is available outside of trial participation.
How did cagrilintide vs tirzepatide compare in REDEFINE 4?
Tirzepatide achieved approximately 25.5% body weight reduction (efficacy estimand) versus approximately 23.0% for CagriSema in REDEFINE 4. Both showed clinically meaningful results. Tirzepatide narrowly outperformed, and holds the added advantages of FDA approval and a substantially larger evidence base.
Can cagrilintide and tirzepatide be combined?
Their receptor systems don't overlap — amylin vs GLP-1/GIP — making a combination mechanistically plausible. No clinical trial has evaluated this specific combination for safety or dosing as of 2026. It should not be attempted outside of a clinical research protocol under medical supervision.
What is cagrilintide's half-life compared to tirzepatide?
Cagrilintide has an approximately 7-day half-life versus tirzepatide's approximately 5 days. Both support once-weekly dosing. Cagrilintide's longer half-life produces slightly steadier plasma concentrations across the dosing week.
Is compounded cagrilintide available through telehealth?
No. Cagrilintide is investigational and cannot be compounded. Compounded tirzepatide is available through licensed telehealth providers subject to provider evaluation, though it is not an FDA-approved compounded formulation.
What are the main side effects of cagrilintide?
Phase 2 trial data identifies nausea and injection-site reactions as the most commonly reported adverse events. Long-term safety data is still accumulating through REDEFINE Phase 3. The overall profile appears broadly similar to GLP-1 receptor agonists.
How does the amylin pathway differ from GLP-1 action?
GLP-1 receptor agonists suppress appetite primarily through hypothalamic incretin pathways and the gut-brain axis. Amylin receptor signaling acts through the brainstem's area postrema and nucleus tractus solitarius — anatomically separate satiety centers. Non-overlapping pathways allow combination use without receptor-level competition.
Where can I start a GLP-1 evaluation through an asynchronous provider?
TelosRX offers asynchronous telehealth evaluation for compounded GLP-1 options including tirzepatide. All cases are reviewed by a licensed provider. Approval is not guaranteed and depends on individual medical history. TelosRX does not offer cagrilintide, which remains available only through clinical trials.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.